


## CLAIMS

1. A compound of the formula (I):



(I)

wherein:


V is selected from  $CH_2$  and  $NH$ , and W is selected from  $NR^1$  and  $NR^2$ ; or V is selected from  $NR^1$  and  $NR^2$ , and W is selected from  $CH_2$  and  $NH$ ;

X is selected from  $CH_2$  and  $CHOH$  in the R or S-configuration;

Y is selected from hydrogen, halogen and hydroxy, except where V is selected from  $NH$ ,  $NR^1$  and  $NR^2$  then Y is hydrogen;


Z is selected from hydrogen, halogen, hydroxy, SQ, OQ and Q, where Q is an optionally substituted alkyl, aralkyl or aryl group;

$R^1$  is a radical of the formula (II)



(II)

$R^2$  is a radical of the formula (III)



5

10

A is selected from N, CH and CR, where R is selected from halogen, optionally substituted alkyl, aralkyl or aryl, OH, NH<sub>2</sub>, NHR<sup>3</sup>, NR<sup>3</sup>R<sup>4</sup> and SR<sup>5</sup>, where R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each optionally substituted alkyl, aralkyl or aryl groups;

15

B is selected from OH, NH<sub>2</sub>, NHR<sup>6</sup>, SH, hydrogen and halogen, where R<sup>6</sup> is an optionally substituted alkyl, aralkyl or aryl group;

D is selected from OH, NH<sub>2</sub>, NHR<sup>7</sup>, hydrogen, halogen and SCH<sub>3</sub>, where R<sup>7</sup> is an optionally substituted alkyl, aralkyl or aryl group;

E is selected from N and CH;

20

G is selected from CH<sub>2</sub> and NH, or G is absent, provided that where W is NR<sup>1</sup> or NR<sup>2</sup> and G is NH then V is CH<sub>2</sub>, and provided that where V is NR<sup>1</sup> or NR<sup>2</sup> and G is NH then W is CH<sub>2</sub>;

25

or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

2. A compound as claimed in claim 1 where Z is selected from hydrogen, halogen, hydroxy, SQ and OQ.

3. A compound as claimed in claim 1 or claim 2 where V is CH<sub>2</sub>.
4. A compound as claimed in any one of claims 1 to 3, where X is CH<sub>2</sub>.
5. A compound as claimed in any one of claims 1 to 4, where G is CH<sub>2</sub>.
6. A compound as claimed in any one of claims 1 to 5 where Z is OH.
7. A compound as claimed in any one of claims 1 to 5 where Z is SQ.
8. A compound as claimed in any one of claims 1, 3, 4 or 5 where Z is Q.
9. A compound as claimed in any one of claims 1 to 8, where W is NR<sup>1</sup>.
10. A compound as claimed in any one of claims 1 to 8, where W is NR<sup>2</sup>.
11. A compound as claimed in any one of claims 1 to 8, where W is selected from NH, NR<sup>1</sup> or NR<sup>2</sup> and X is CH<sub>2</sub>.
12. A compound as claimed in any one of claims 1, 2, 3, 4, 5, 6 or 9 where V, X and G are all CH<sub>2</sub>, Z is OH and W is NR<sup>1</sup>.
13. A compound as claimed in any one of claims 1, 2, 3, 4, 5, 7 or 9 where V, X and G are all CH<sub>2</sub>, Z is SQ and W is NR<sup>1</sup>.
14. A compound as claimed in any one of claims 1 to 13 where Y is hydrogen.
15. A compound as claimed in any one of claims 1 to 13 where Y is hydroxy.
16. A compound as claimed in any one of claims 1 to 15 where B is hydroxy.
17. A compound as claimed in any one of claims 1 to 15 where B is NH<sub>2</sub>.

18. A compound as claimed in any one of claims 1 to 17 where A is CH.

19. A compound as claimed in any one of claims 1 to 17 where A is N.

5 20. A compound as claimed in any one of claims 1 to 19 where D is H

21. A compound as claimed in any one of claims 1 to 19 where D is NH<sub>2</sub>.

22. A compound as claimed in any one of claims 1 to 21 where E is N.

10

23. A compound as claimed in claim 1, which is:

(3R,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

15 (3R,4R)-1-[(9-Deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4R)-1-[(8-aza-9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

(3R,4R)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;

20 (3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(2-phenylethyl)pyrrolidine;

(3S,4R)-1-[(9-deazahypoxanthin-9-yl)methyl]-3,4-dihydroxy-4-methylthiomethylpyrrolidine;

25 (3R,4S)-1-[(9-deazahypoxanthin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;

*N*-(9-Deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol;

*N*-(9-deazahypoxanthin-9-yl)methyl-1,4-dideoxy-1,4-imino-D-ribitol;

(3R,4R)-3-hydroxy-4-hydroxymethyl-1-(hypoxanthin-9-yl)pyrrolidine;

30 (3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(methylthiomethyl)pyrrolidine;

(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;

(3R,4S)-1-[(8-aza-9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(benzylthiomethyl)pyrrolidine;

- (3R,4R)-1-[(9-deazaguanin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;  
(3R,4S)-1-[(9-deazaadenin-9-yl)methyl]-3-hydroxy-4-(4-chlorophenylthiomethyl)pyrrolidine;  
5 (3R,4R)-1-[(6-chloro-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine;  
(3R,4R)-1-[(6-azido-9-deazapurin-9-yl)methyl]-3-hydroxy-4-(hydroxymethyl)pyrrolidine; or  
(3R,4R)-1-[(9-deazaadenin-9-yl)methyl]-3-acetoxy-4-  
10 (acetoxymethyl)pyrrolidine;  
or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.
24. A pharmaceutical composition comprising a pharmaceutically effective  
15 amount of a compound as claimed in any one of claims 1 to 23.
25. A method of treating a disease or condition in which it is desirable to inhibit  
purine phosphoribosyltransferase, purine nucleoside phosphorylase, 5'-  
methylthioadenosine phosphorylase, 5'-methylthioadenosine nucleosidase  
20 and/or nucleoside hydrolase comprising administering a pharmaceutically  
effective amount of a compound as claimed in any one of claims 1 to 23 to a  
patient requiring treatment.
26. The method of claim 25, where the disease or condition is cancer, bacterial  
25 infection, protozoal infection or a T-cell mediated disease.
27. The method of claim 26, where the T-cell mediated disease is psoriasis,  
arthritis or transplant rejection.
- 30 28. The use of a compound as claimed in any one of claims 1 to 23 in the  
manufacture of a medicament for treating a disease or condition in which it is  
desirable to inhibit purine phosphoribosyltransferase, purine nucleoside  
phosphorylase, 5'-methylthioadenosine phosphorylase, 5'-  
methylthioadenosine nucleosidase and/or nucleoside hydrolase.